Johnson & Johnson Veteran with 25-Year Tenure Joins BD as President of Interventional Segment

On May 18, 2026, global medical device giant BD (Becton, Dickinson and Company) announced a senior executive appointment,Peter Menziuso will assume the role of Executive Vice President and President of BD's Interventional Business on June 1.

Menziuso has over 30 years of global medical leadership experience, with a 25-year tenure at Johnson & Johnson, and his most recent position wasChairman of Johnson & Johnson Vision Care.

BD Chairman, CEO and President Tom Polen commented in the announcement: "BD's interventional business has an outstanding track record, and Peter is the right person to continue this momentum and achieve further success." He also noted that Menziuso combines strategic leadership with operational discipline, while focusing on customers, patients, and team building.

BD's interventional business covers product lines such as peripheral intervention, oncology, surgery, and urology.BD has repeatedly referred to its interventional business as a "differentiated growth engine" in its financial reports. This segment also needs to strike a balance between scale expansion and operational efficiency.

Johnson & Johnson Vision Care has an annual revenue of $5 billion, covering multiple lines such as commercial operations, R&D, supply chain, quality, finance, and medical affairs.

Johnson & Johnson Vision Care's business attributes lie between consumer healthcare and surgical devices, with high demands on supply chain stability, the standardization of global commercial execution, and the collaborative efficiency of scaled teams.Request. Menziuso's resume description also confirms this, consolidating market leadership, transforming strategy into continuous performance growth through rigorous business execution, and building a highly efficient team.

Chairman of BD, TomPolen emphasized "rigorous execution," "continuous performance growth," and "a strong team" three times in the announcement of Menziuso's appointment. This set of phrases is consistent with Menziuso.Description of Public Actions During the Johnson & Johnson PeriodDegree of overlap.

In other words, BD has brought in an operator validated in a $5 billion consumer healthcare business. He excels at prioritizing product portfolios, building supply chain resilience, and establishing standardized processes for global commercial execution.The announcement did not elaborate on how these practices will be modified or utilized in the intervention business.Follow-up can focus on BD intervention business in R&D investment structure, regional market strategySlightly andActual changes in operational cost control.

The content of this article is for reference only and does not constitute investment advice. Readers are advised to effectively distinguish.If any platform reprints this article, it must take responsibility for the content of the article. Medical Device Business Review is not responsible for the impact of secondary dissemination caused by the reprint.